CureVac Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Alexander Zehnder
Chief executive officer
€978.3k
Total compensation
| CEO salary percentage | 51.1% |
| CEO tenure | 1.1yrs |
| CEO ownership | n/a |
| Management average tenure | 1.3yrs |
| Board average tenure | 8.2yrs |
Recent management updates
Recent updates
We Think CureVac (NASDAQ:CVAC) Needs To Drive Business Growth Carefully
Mar 20
CureVac: No Momentum In Sight
Mar 08What Does The Future Hold For CureVac N.V. (NASDAQ:CVAC)? These Analysts Have Been Cutting Their Estimates
Aug 26CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 89% Above Its Share Price
Jun 14Some Analysts Just Cut Their CureVac N.V. (NASDAQ:CVAC) Estimates
May 01Analysts Have Lowered Expectations For CureVac N.V. (NASDAQ:CVAC) After Its Latest Results
Apr 29An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 46% Undervalued
Jan 08CureVac BV reports Q2 results
Aug 18CureVac claims patent rights for Pfizer/BioNTech COVID-19 vaccine
Jul 05Will CureVac (NASDAQ:CVAC) Spend Its Cash Wisely?
May 29Analysts Are Betting On CureVac N.V. (NASDAQ:CVAC) With A Big Upgrade This Week
May 02A Look At The Intrinsic Value Of CureVac N.V. (NASDAQ:CVAC)
Oct 28CureVac: Wait For Concrete News Before Investing
Sep 01CureVac plunges as COVID-19 vaccine candidate indicates below par efficacy
Jun 16An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 31% Undervalued
Jun 13CureVac tumbles on potential delay for European decision on its COVID-19 shot
Jun 08CureVac: The Moment Of Truth Arrives
Jun 01CureVac BV reports Q1 results
May 26CureVac Could Soon Join The Fight Against COVID-19
May 10CureVac N.V.'s (NASDAQ:CVAC) Has Found A Path To Profitability
May 02How Much Of CureVac N.V. (NASDAQ:CVAC) Do Insiders Own?
Mar 03CureVac expands Phase 1 Trial for CV8102 in advanced Melanoma
Feb 04Analysts Are Optimistic We'll See A Profit From CureVac N.V. (NASDAQ:CVAC)
Jan 27CureVac's COVID-19 vaccine shows promise in preclinical study of non-human primates
Jan 11CureVac, Bayer agree to COVID-19 vaccine alliance - report
Jan 07Have Insiders Been Buying CureVac N.V. (NASDAQ:CVAC) Shares?
Dec 23Curevac advances COVID-19 vaccine candidate to Phase 3 trial
Dec 21CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | €978k | €500k | -€260m |
Compensation vs Market: Alexander's total compensation ($USD1.05M) is below average for companies of similar size in the US market ($USD2.41M).
Compensation vs Earnings: Insufficient data to compare Alexander's compensation with company performance.
CEO
Alexander Zehnder (53 yo)
1.1yrs
Tenure
€978,331
Compensation
Dr. Alexander Zehnder, M.D, MBA, is Chief Executive Officer at CureVac N.V. since April 01, 2023 and is its Managing Director since March 2023 and serves as its Member of Management Board since 2023. He se...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, MD & Member of Management Board | 1.1yrs | €978.33k | no data | |
| MD, CFO & Member of Management Board | 7.6yrs | €654.18k | 0.032% € 191.7k | |
| COO, Member of Management Board & MD | 2.8yrs | €600.74k | 0.00093% € 5.5k | |
| Chief Development Officer | 1.3yrs | €614.49k | no data | |
| Senior VP & Area Head of Oncology | 1.3yrs | €284.15k | no data | |
| Vice President Corporate Communications & Investor Relations | no data | no data | no data | |
| General Counsel | no data | no data | no data | |
| Head of Corporate Communications | no data | no data | no data | |
| Head of Human Resources | no data | no data | no data | |
| Senior Vice President of Technology | no data | no data | no data | |
| Senior Vice President of Science & Innovation | no data | no data | no data | |
| Head of Intellectual Property | no data | no data | no data |
1.3yrs
Average Tenure
53yo
Average Age
Experienced Management: CVAC's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Scientific Director of Immunology and Member of Scientific Advisory Board | no data | no data | no data | |
| Supervisory Board Member | 4.9yrs | €96.25k | 0.0011% € 6.5k | |
| Member of Scientific Advisory Board | 8.2yrs | no data | no data | |
| Independent Director of Supervisory Board | less than a year | €51.03k | no data | |
| Independent Chairman of Supervisory Board | 8.8yrs | €123.75k | 0.0031% € 18.1k | |
| Member of Scientific Advisory Board | 8.2yrs | no data | no data | |
| Member of Scientific Advisory Board | 8.2yrs | no data | no data | |
| Member of Scientific Advisory Board | 8.2yrs | no data | no data | |
| Member of Scientific Advisory Board | 8.2yrs | no data | no data | |
| Supervisory Board Member | 8.8yrs | €96.25k | 0.0014% € 8.3k | |
| Member of Scientific Advisory Board | 8.2yrs | no data | no data | |
| Member of Scientific Advisory Board | 8.2yrs | no data | no data |
8.2yrs
Average Tenure
63yo
Average Age
Experienced Board: CVAC's board of directors are considered experienced (8.2 years average tenure).